Hester Biosciences — 360° view

Hester Biosciences, a company in the Pharmaceuticals industry, reported revenue of ₹98 crore and net profit of ₹21 crore for the September 2026 quarter.

Hester Biosciences (NSE: HESTERBIO) closed at ₹2,329.90 on 20 Nov 2026, up 37.4% over the past year. Its market capitalisation is ₹1,982 crore and it trades at 33.8 times earnings.

Share price
₹2,329.90 (20 Nov 2026)
Market cap
₹1,982 Cr (20 Nov 2026)
P/E
33.76 (20 Nov 2026)
Revenue
₹98 Cr (September 2026 quarter)
Net profit
₹21 Cr (September 2026 quarter)
ROCE
15.2% (FY26)
ROE
15.9% (FY26)
Book value
₹550 (FY26)
Dividend yield
0.47% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,683.60 / ₹1,239.30 (20 Nov 2026)
1-year return
37.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: HESTERBIO

Incorporated in 1987, Hester Biosciences Ltd is one of India’s leading animal healthcare companies and a major manufacturer of poultry and animal vaccines, including a leading position in PPR and Goat Pox vaccines.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.